An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
PainCancer
Interventions
DRUG

Fentanyl

Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).

Trial Locations (1)

Unknown

Kitakyushu

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT00641667 - An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain | Biotech Hunter | Biotech Hunter